Author(s):
De Marchi, Adriano Francisco [UNESP] ; de Macedo, Ana Bárbara Trizzotti [UNESP] ; Soares, Carlos Segundo Paiva [UNESP] ; Bolfi, Fernanda [UNESP] ; Iessi, Mariana Riello Gomes [UNESP] ; de Oliveira, Cristiano Claudino [UNESP] ; Koga, Katia Hiromoto [UNESP] ; Moriguchi, Sonia Marta [UNESP] ; Tagliarini, José Vicente [UNESP] ; da Silva Mazeto, Gláucia Maria Ferreira [UNESP]
Date: 2022
Persistent ID: http://hdl.handle.net/11449/230131
Origin: Oasisbr
Subject(s): prognosis; thyroglobulin; Thyroid neoplasms
Description
Made available in DSpace on 2022-04-29T08:38:05Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-11-03
Objective: Thyrotropin-stimulated thyroglobulin (STg) after total thyroidectomy is a prognosis marker for differentiated thyroid carcinoma (DTC). As Tg level is influenced by thyrotropin (TSH), perhaps the STg/TSH ratio is also a prognosis marker for these tumours. We aimed to compare STg/TSH ratio and first STg level in differentiated thyroid carcinoma patients for their ability to predict the long-term response to initial treatment. Methods: This retrospective study evaluated data from 181 DTC patients for first (1st) STg and STg/TSH ratio, at 1-3 months post-total thyroidectomy and before iodine-131 therapy, according to response to initial therapy [Excellent/Indeterminate or Incomplete (Biochemical/Structural)] observed at final evaluation, and with the survival time with excellent/indeterminate response. Results: Cases with incomplete response presented higher STg level [225.13 ± 585.26 ng/mL versus (vs) 20.4 ± 192.9 ng/mL; p < 0.001] and STg/TSH ratio (3.01 ± 7.8 vs 0.27 ± 2.58; p < 0.001). Cutoffs of 5 ng/mL for STg and 0.085 for STg/TSH displayed sensitivities of 76.7% and 76.9%, and specificities of 79.2% and 82.6%, respectively, in predicting response to therapy. Values below these cutoffs were associated with longer survival time in excellent/indeterminate response (140.4 vs 15.9 and 144.6 vs 15.9 months, respectively). Conclusion: STg/TSH ratio has a similar performance to the 1st STg in predicting long-term response to initial therapy.
Departamento de Clínica Médica Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Oftalmologia Otorrinolaringologia e Cirurgia de Cabeça e Pescoço Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Patologia Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Medicina Nuclear Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Clínica Médica Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Oftalmologia Otorrinolaringologia e Cirurgia de Cabeça e Pescoço Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Patologia Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
Departamento de Medicina Nuclear Faculdade de Medicina de Botucatu Universidade Estadual Paulista (Unesp)
